Tag Archives: Jason Mccarthy

Sophiris Bio (SPHS) Receives a Buy from Maxim Group

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Sophiris Bio (SPHS – Research Report), with a price target of $6. The company’s shares closed on Tuesday at $2.10, close to its 52-week low

Maxim Group Remains a Buy on Immutep Limited (IMMP)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Immutep Limited (IMMP – Research Report), with a price target of $7. The company’s shares closed yesterday at $2.66. McCarthy observed: “Immutep presented data from

Maxim Group Maintains a Buy Rating on Mesoblast Ltd (MESO)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast Ltd (MESO – Research Report) today and set a price target of $16. The company’s shares opened today at $4.80, close to its 52-week low of $4.58. McCarthy said:

Cancer Genetics (CGIX) Gets a Hold Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Hold rating on Cancer Genetics (CGIX – Research Report) today. The company’s shares opened today at $0.45, close to its 52-week low of $0.30. McCarthy wrote: “Cancer Genetics (CGI) reported 3Q18 with revenues

Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group Inc (NASDAQ: SLS) and Arena Pharma (NASDAQ: ARNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SELLAS Life Sciences Group Inc (SLS – Research Report) and Arena Pharma (ARNA – Research Report) with bullish sentiments. SELLAS Life Sciences

Maxim Group Thinks Adial Pharmaceuticals Inc’s Stock is Going to Recover

Maxim Group analyst Jason McCarthy maintained a Buy rating on Adial Pharmaceuticals Inc (ADIL – Research Report) today and set a price target of $5. The company’s shares opened today at $1.27, close to its 52-week low of $1.11. McCarthy